Haematology

Donor T-cells prevent CMV complications in blood cancer patients

The FDA approved a new donor T-cell therapy to prevent cytomegalovirus (CMV) infection and disease in high-risk blood cancer patients post-transplant.

MAHA Monday: The Rush to Publish and Its Clinical Fallout

The annual 'MAHA Monday' sees a deluge of abstracts for the American Society of Hematology meeting, creating a bottleneck for peer review and raising questions about the quality of early data dissemination.

Liso-Cel Delivers Durable OS Benefit in R/R LBCL, Redefining Treatment

Lisocabtagene maraleucel (liso-cel) significantly extended overall survival in relapsed/refractory large B-cell lymphoma, establishing a new benchmark for second-line therapy.

New Regimen Confers 'Meaningful' Benefit in Aggressive Lymphoma

A novel treatment regimen has demonstrated significant clinical benefit in patients with aggressive lymphoma, potentially establishing a new standard of care.

FDA Expands Casgevy for Sickle Cell in Children 2 Years and Older

The FDA expanded Casgevy's approval to include children aged 2 to 11 with sickle cell disease, offering a gene-editing therapy for this severe genetic disorder.

Monoclonal Antibodies May Complicate Transfusion Testing

Monoclonal antibodies, particularly IgG4 anti-CD47, may induce erythrophagocytosis and interfere with transfusion compatibility testing, posing a challenge for patient management.

Blood Transfusion Safety: Pathogen Inactivation Reduces Transfusion-Transmitted Infections

Modern blood transfusion practices, including pathogen inactivation, have significantly reduced the risk of transfusion-transmitted infections, improving patient safety.

Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)

Chemotherapy-free regimens for pediatric acute promyelocytic leukemia (APL) demonstrate superior efficacy and reduced toxicity compared to traditional chemotherapy.

Personalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches

EHA 2026 discussions focused on individualized hemophilia care, moving beyond standard prophylaxis to tailored treatment strategies based on patient-specific factors.